New six-year data for a defocus lens by Hoya marks the longest study of a myopia control spectacle lens – and answers key questions about rebounding effects and whether the control effect is sustained over time. Read more
RANZCO myopia position paper: Why outdoor time is essential
RANZCO has published a new position paper on myopia, advocating for a more nuanced public health policy that incorporates increased outdoor time to limit progression in children while protecting against UV light exposure. Read more
Change agents: educating parents about myopia
Research estimates myopia will affect 50% of the world by 2050, and recent COVID lockdowns appear to have only worsened the situation. As more patients – and their parents – seek effective interventions, practitioners should prepare to meet this oncoming public health demand. Read more
SightGlass Vision specs’ two-year data demonstrates myopia control efficacy
Spectacles that use SightGlass Vision’s trademarked Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children, based on 24-month interim data from its pivotal multisite clinical study. Read more
Covering all bases of myopia management
Myopia’s prevalence has spawned all-new innovation and unexpected collaborations. One of those is a three-way company alliance promising Australian optometrists a new one-two approach to myopia management. Read more
EssilorLuxottica-CooperCompanies myopia specs joint venture ‘comes to life’
The first SightGlass Vision myopia spectacles are starting to reach the market as EssilorLuxottica and CooperCompanies announce their joint venture has commenced operation. Read more
Low-dose atropine EIKANCE secures first myopia TGA approval
The Therapeutic Goods Administration (TGA) has approved EIKANCE 0.01%, Australia’s first low-dose atropine eye drop for myopia progression in children and young teenagers. Read more
New data confirms it’s never too late to start myopia treatment
Data from a six-year multicentre clinical trial confirms that CooperVision MiSight 1 day contact lenses provide myopia control for nearly all children, according to a new peer review paper. Read more
Seven-year study shows no myopia control rebound in children wearing MiSight contact lens
New seven-year findings from CooperVision’s MiSight 1 day contact lens clinical trial shows no evidence of myopia control rebound in children 12 months after treatment has ended. Read more
New paper sheds light on myopia control axial length targets
A new paper comparing axial elongation differences among untreated myopes, myopes fitted with a control contact lens and emmetropes has helped further the understanding of myopia control efficacy in the context of normal childhood eye growth. Read more